Sunstone Capital backs Adenium Biotech

Equity was invested from Sunstone Life Science Ventures Fund III. The investment will be used to select a drug candidate for clinical trials.

Previous funding
Novo Seeds initially backed Adenium's spin-off from biotech company Novozymes in 2011, investing DKK 11m.

Company
Adenium, established in 2011, seeks to develop a pharmaceutical from Arenicin, an antibacterial compound found in sand worms. Company researchers believe the drug could be used against multiresistant gram-negative bacteria, which cause problems in hospital settings and are difficult to treat using traditional antibiotics. Adenium is based in Copenhagen, Denmark.

People
Partner Andreas Segerros worked on the deal for Sunstone.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Denmark
• Sunstone Capital A/S